利多卡因/碳酸氢钠(Lidocaine/Sodium bicarbonate) - 药物靶点：SCNA_专利_临床

概要

基本信息

药物类型

小分子化药

别名

PSD 597、PSD-597

靶点

SCNA

作用机制

SCNA调节剂(钠通道α亚基家族调节剂)

治疗领域

泌尿生殖系统疾病其他疾病

在研适应症-

非在研适应症

间质性膀胱炎

原研机构

Plethora Solutions Ltd.

在研机构-

非在研机构

Plethora Solutions Ltd.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C14H22N2O

InChIKeyNNJVILVZKWQKPM-UHFFFAOYSA-N

CAS号137-58-6

查看全部结构式(2)

关联

7

项与利多卡因/碳酸氢钠相关的临床试验

NCT03343080 / Completed临床2期IIT

Lidocaine as an ETT Cuff Media in the Immediate Post-operative Cardiac Surgery Patient Population, and Its Effect on Sedation/Analgesia Requirements: a Pilot Study

Researchers will compare the effects of lidocaine versus air, as a way to fill the breathing tube cuff which is gently inflated to hold in place the trachea (airway) during surgery. Air is the traditional method used to inflate the breathing tube cuff. Researchers wish to find if lidocaine works better than air to facilitate tolerance to the breathing tube (decreased coughing, sore throat, hoarseness). They also want to learn more about its effectiveness for this particular surgical intervention.

开始日期2018-07-27

申办/合作机构

Mayo Clinic

IRCT201709199014N186 / Recruiting临床2期IIT

Comparison of the effect of lidocaine-bicarbonate, lidocaine-dexamethasone and lidocaine alone for digital block in patients with figure injury: a double blind randomized clinical trial

开始日期2017-05-28

申办/合作机构-

NCT03107754 / Completed临床4期IIT

Buffered Lidocaine for Paracervical Block to Decrease Injection Pain During First Trimester Uterine Aspirations

For pain relief during a first trimester surgical aspiration, most providers use the paracervical block, either alone or in combination with other pain control techniques. Some providers use buffered lidocaine due to a belief that it decreases pain. Others use plain lidocaine. At our clinics, the standard pain management protocol is using 20 cc of 1% plain lidocaine in a two site injection. Few studies have compared buffered versus unbuffered lidocaine for paracervical blocks during first trimester uterine aspirations. This study seeks to determine if buffered lidocaine decreases injection pain versus plain lidocaine for paracervical blocks.

开始日期2017-05-15

申办/合作机构

University of Hawaii System

100 项与利多卡因/碳酸氢钠相关的临床结果

登录后查看更多信息

100 项与利多卡因/碳酸氢钠相关的转化医学

登录后查看更多信息

100 项与利多卡因/碳酸氢钠相关的专利（医药）

登录后查看更多信息

3

项与利多卡因/碳酸氢钠相关的文献（医药）

2017-09-01·Journal of the American College of Radiology : JACR2区 · 医学

Impact of Sodium Bicarbonate-Buffered Lidocaine on Patient Pain During Image-Guided Breast Biopsy

2区 · 医学

Article

作者: Soo, Mary Scott C ; Shelby, Rebecca A ; Vasan, Alison ; Baker, Jay A

PURPOSE:

This randomized, double-blind controlled study evaluated the effectiveness of sodium bicarbonate-buffered lidocaine on reducing pain during imaging-guided breast biopsies.

MATERIALS AND METHODS:

This prospective, HIPAA-compliant study randomly assigned 85 women undergoing ultrasound- or stereotactic-guided core-needle breast biopsies to receive intradermally and intraparenchymally either 1% lidocaine buffered with sodium bicarbonate (9:1 ratio) (bicarbonate study group) or 1% lidocaine alone (control group). Pain was evaluated using a 0-to-10 Likert pain scale during both intradermal and intraparenchymal anesthesia injections and during tissue sampling. Prebiopsy breast pain, anxiety, medical history, demographics, biopsy type, radiologist level of training, breast density, and lesion histology were recorded. Data were analyzed using analysis of variance and analysis of covariance.

RESULTS:

Unadjusted mean pain scores were 1.47 and 2.07 (study and control groups, respectively; P = .15) during intradermal injections, and 1.84 and 2.98 (study and control groups, respectively; P = .03) during intraparenchymal injections. Tissue sampling mean pain scores were .81 and 1.71 (study and control groups, respectively; P = .07). Moderator analyses found (1) among patients with preprocedural pain, those in the bicarbonate group experienced less intradermal injection pain (0.85 ± 1.23) than patients in the control group (2.50 ± 2.09); (2) among patients with fatty or scattered fibroglandular tissue, those in the bicarbonate group (1.35 ± 1.95) experienced less intraparenchymal injection pain than the control group (3.52 ± 3.13); and (3) during ultrasound-guided biopsies, patients in the bicarbonate group experienced less tissue-sampling pain (0.23 ± 0.63) than the control group (1.79 ± 3.05).

CONCLUSIONS:

Overall, buffering lidocaine with sodium bicarbonate significantly reduced pain during intraparenchymal injections, and additional pain reduction was found in certain patient subgroups during intradermal injections, intraparenchymal injections, and tissue sampling.

2015-01-01·Journal of endodontics2区 · 医学

Effect of Sodium Bicarbonate–buffered Lidocaine on the Success of Inferior Alveolar Nerve Block for Teeth with Symptomatic Irreversible Pulpitis: A Prospective, Randomized Double-blind Study

2区 · 医学

Article

作者: Baghaei, Badri ; Saatchi, Masoud ; Noormohammadi, Hamid ; Khademi, Abbasali

INTRODUCTION:

The purpose of this prospective, randomized, double-blind study was to compare the anesthetic efficacy of buffered with nonbuffered 2% lidocaine with 1:80,000 epinephrine solution for inferior alveolar nerve (IAN) block in patients with mandibular posterior teeth experiencing symptomatic irreversible pulpitis.

METHODS:

Eighty adult patients diagnosed with symptomatic irreversible pulpitis of a mandibular posterior tooth were selected. The patients received 2 cartridges of either 2% lidocaine with 1:80,000 epinephrine buffered with 0.18 mL 8.4% sodium bicarbonate or 2% lidocaine with 1:80,000 epinephrine with 0.18 mL sterile distilled water using conventional IAN block injections. Endodontic access preparation was initiated 15 minutes after injection. Lip numbness was required for all the patients. Success was determined as no or mild pain on the basis of Heft-Parker visual analog scale recordings upon access cavity preparation or initial instrumentation. Data were analyzed by the t, Mann-Whitney, and chi-square tests.

RESULTS:

The success rates were 62.5% and 47.5% for buffered and nonbuffered groups, respectively, with no significant differences between the two groups (P = .381).

CONCLUSIONS:

Buffering the 2% lidocaine with 1:80,000 epinephrine with 8.4% sodium bicarbonate did not improve the success of the IAN block in mandibular molars in patients with symptomatic irreversible pulpitis.

2009-04-01·BJU international2区 · 医学

Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome

2区 · 医学

Article

作者: Edward L. Davis ; Michael G. Wyllie ; J. Curtis Nickel ; Richard A. Henry ; Soledad Lee ; Robert Moldwin

OBJECTIVE:

To assess the immediate and sustained relief of the symptoms of interstitial cystitis/painful bladder syndrome (IC/PBlS) after a consecutive 5‐day course of treatment with intravesical alkalinized lidocaine (PSD597), and to characterize the pharmacokinetics of single and multiple doses of intravesical PSD597 in a subgroup of patients.

PATIENTS AND METHODS:

In all, 102 adult patients (99 women) with a clinical diagnosis of IC/PBlS were randomized from 19 centres in the USA and Canada to receive a daily intravesical instillation of PSD597 (200 mg lidocaine, alkalinized with a sequential instillation of 8.4% sodium bicarbonate solution, to a final volume of 10 mL) or placebo (double‐blind), for 5 consecutive days. Patients were followed at intervals up to 29 days after the first instillation. Efficacy was assessed by changes in the Global Response Assessment (GRA), Likert scales for bladder pain, urgency and frequency, and validated O’Leary‐Sant IC symptom and problem indices.

RESULTS:

Significantly more patients treated with PSD597 rated their overall bladder symptoms as moderately or markedly improved on the GRA scale 3 days after completing the 5‐day course of treatment (30% and 9.6%, respectively, for patients treated with PSD597 and placebo; P = 0.012). The treatment effects were also maintained beyond the end of treatment and are further supported by the secondary endpoints, including symptom and problem indices. The peak serum lidocaine concentration during the study was <2 µg/mL, and well below the toxic level (>5 µg/mL).

CONCLUSION:

This preliminary study showed that PSD597 was effective for providing sustained amelioration of symptoms of IC/PBlS beyond the acute treatment phase. The drug was safe, well tolerated and devoid of the systemic side‐effects often experienced with oral drug administration. Long‐term studies are needed to determine the optimum regimen to maintain this favourable treatment effect.

100 项与利多卡因/碳酸氢钠相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
间质性膀胱炎	临床2期	-	Plethora Solutions Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03107754 (CTgov)	临床4期	疼痛	98	Lidocaine (Standard Paracervical Block)	繭蓋積夢糧膚壓築鏇衊(簾鏇憲獵壓選簾衊襯膚) = 鑰鹽製範遞艱構艱遞淵廠顧繭觸淵鹹選顧淵遞 (餘廠壓願繭齋觸鹽憲遞, 醖憲築築積夢餘鑰夢鑰 ~ 廠鏇獵網遞鹽簾選構衊) 更多	-	2020-05-15
				Lidocaine-Sodium Bicarbonate (Buffered Lidocaine Paracervical Block)	繭蓋積夢糧膚壓築鏇衊(簾鏇憲獵壓選簾衊襯膚) = 壓鹹齋餘顧積鹽襯蓋夢廠顧繭觸淵鹹選顧淵遞 (餘廠壓願繭齋觸鹽憲遞, 夢餘鑰繭襯鹽窪壓醖積 ~ 範鑰憲艱願選淵繭襯繭) 更多